ABMT (Advanced BioMedical Technologies) Debt-to-Equity: -0.00 (As of Jul. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced BioMedical Technologies Debt-to-Equity?

Advanced BioMedical Technologies ABMT Debt-to-Equity is -0.00 as of Jul. 2021.

Advanced BioMedical Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2021 was $0.01 Mil. Advanced BioMedical Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2021 was $0.00 Mil. Advanced BioMedical Technologies's Total Stockholders Equity for the quarter that ended in Jul. 2021 was $-8.18 Mil. Advanced BioMedical Technologies's debt to equity for the quarter that ended in Jul. 2021 was -0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Advanced BioMedical Technologies's Debt-to-Equity or its related term are showing as below:

ABMT's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Advanced BioMedical Technologies  (OTCPK:ABMT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Advanced BioMedical Technologies Debt-to-Equity Related Terms

Advanced BioMedical Technologies Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Advanced BioMedical Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies Debt-to-Equity Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.01

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.00 -0.00 -0.00

ABMT vs VYCO, ADMT, THMO: Debt-to-Equity Comparison

For the Medical Devices subindustry, Advanced BioMedical Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced BioMedical Technologies Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's Debt-to-Equity falls into.


Advanced BioMedical Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Advanced BioMedical Technologies's Debt to Equity Ratio for the fiscal year that ended in Oct. 2020 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.028 + 0.007) / -7.402
=-0.00

Advanced BioMedical Technologies's Debt to Equity Ratio for the quarter that ended in Jul. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.011 + 0) / -8.182
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.00 mean?
Advanced BioMedical Technologies (ABMT) has a Debt-to-Equity of -0.00 as of Jul. 2021. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Advanced BioMedical Technologies and its competitors.
Is Advanced BioMedical Technologies' Debt-to-Equity too high?
Advanced BioMedical Technologies' current Debt-to-Equity is -0.00.
How does Advanced BioMedical Technologies' Debt-to-Equity compare to VYCO and ADMT?
Advanced BioMedical Technologies' Debt-to-Equity of -0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Advanced BioMedical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced BioMedical Technologies's current Debt-to-Equity is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current Debt-to-Equity of -0.00. The current Debt-to-Equity is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current Debt-to-Equity is -0.00 as of Jul. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced BioMedical Technologies Business Description

Address 535 Fifth Avenue, 4th Floor, New York, NY, USA, 10017
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.